Analogic — 36th Annual JP Morgan Healthcare Conference (January 2018)
23 slides from Analogic's conference presentation, Jan 11, 2018
Slide 1: 50 Years of Imaging Innovation
50 years of imaging innovation 36th Annual JP Morgan Healthcare conference Fred parks, president and CEO January 11, 2018 Exhibit 99.1
Slide 2: Safe Harbor
Safe Harbor Any statements about future expectations, plans, and prospects for the Company, including statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation
Slide 3: Use of Non-GAAP Financial Measures
This presentation includes non-GAAP financial measures that are not in accordance with, nor an alternative to, generally accepted accounting principles and may be different from such non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive se
Slide 4: Years of Imaging Innovation
50 Years of Imaging Innovation Founded on advanced CT imaging technology in 1967 Innovative healthcare and security solutions with extensive patent portfolio and know how Strategic redirection and lean operating structure yielding improved profitability in FY18
Slide 5: Investment Thesis
Investment Thesis Imaging Technologies in Medical, Ultrasound and Security Markets Create Opportunities Expanding into New and Existing Markets Focusing on Execution will Drive Value Improving Operating Leverage on Lower Cost Structure Exploring Strategic Alternatives for Accelerated Value Creation
Slide 6: Market-Leading Advanced Image Technology
Market-Leading Advanced Image Technology
Slide 7: Organic Strategic Focus Businesses Returning to Growth
Organic Strategic Focus Businesses Returning to Growth Medical Imaging Returning to historical levels with high margins Security is in Build mode with new opportunities Ultrasound is Refocused for above-market growth Commitment to productive cost structure Accelerates earnings growth More than $24 m
Slide 8: Our Business Segments
Our Business Segments Medical Imaging Ultrasound Security & Detection 57% of revenues* 30% of revenues* 13% of revenues* Migrating from CT components to CT systems Growing OEM base with differentiated offerings Drive growth in emerging markets Re-focusing in Urology (#1) and Surgery (#2) Revitalizin
Slide 9: Medical Imaging
Medical Imaging
Slide 10: Medical Imaging Business Update
CT Mammo MRI Medical Imaging Business Update CT gantry growth in China progressing; 200+ systems Growing OEM customer base with new gantry offerings OEM sourcing decision impacts FY18 revenue Long-term contracts with major OEMs Growth opportunities at 1.5T and 3.0T with existing OEMs Longer-term gro
Slide 11: Ultrasound
ULTRASOUND
Slide 12: Re-Focused Ultrasound Portfolio to Growth and with Improved Cost Structure
Re-Focused Ultrasound Portfolio to Growth and with Improved Cost Structure Surgery #2 bk5000 Urology #1 bk3000 Urology #1 Global Market Position Established global installed base Adoption of integrated bkFusion MRI Ultrasound Fusion driving high-end system sales Upcoming replacement cycle opportunit
Slide 13: Ultrasound Business Update
Probes Sales Channel Surgery Urology Ultrasound Business Update Solidifying #1 position in urology with bk3000 Differentiated probe offering New opportunities in Fusion with partner MIM Solid #2 player in surgery market New bk5000 gaining traction; driving growth in Q1 FY18 Small cavity, sterilizabl
Slide 14: Security and Detection
Security and Detection
Slide 15: Security Business Update
Global Check-point Rapid DNA Int’l Checked US Checked Security Business Update Continued demand for refurbishment and medium-speed system replacements Stable business over the foreseeable future Smiths XCT high-speed success at large international airports Positioning for value-conscious, smaller ai
Slide 16: Outlook
Outlook
Slide 17: Q1 FY18 Business Summary
Q1 FY18 Business Summary Encouraged by Q1 Ultrasound performance Re-focused strategy on core business driving positive results led by strength in surgical ultrasound sales Benefits of prior year cost reductions yielding improved profitability Security gaining traction with high speed and ConneCT Str
Slide 18: FY 2018 Outlook
FY 2018 Outlook* Optimistic after Q1 FY18 performance, FY17 cost reductions continue to drive profitability Ultrasound: Low-single-digit non-GAAP operating margin on low-single-digit revenue decline Core growth in optimized Urology / Surgery portfolio Lower annual operating expenses by $20 million M
Slide 19: Strategic Alternatives for Value Creation
Strategic Alternatives for Value Creation As previously announced, our Board of Directors has initiated a process for the sale of the whole Company to maximize value for shareholders on an accelerated timeline Engaged Citi as financial advisor Continuing to focus on strategic sale process while driv
Slide 20: Thank You
Thank You OVERVIEW
Slide 21: Non-GAAP Reconciliation
Non-Gaap Reconciliation Gi \ OVERVIEW analogic”
Slide 22: Reconciliation (in thousands, except per share data)
(in thousands, except per share data) ‘Twelve Months Ended “FayS 203 Tay 20 uly 02018 uly 31,2016 July 31,2017 GAAP Income (Loss) From Operations s 45375 $s 2908S 4059 25213 -$ (66,760) Share-based compensation expense 11,601 usr 10.938 8,797 9431 [BK Medical distributor matter inquiry related costs
Slide 23: Reconciliation of Income from Operations
(in thousands, except per share data) ‘Twelve Months Ended July 31,2013 _Juby 31,2014 _ July 31,2018 ‘GAAP Income (Loss) from Operations S 31864 $3108. $7905 SaaS $37.95. Star tted compensation expense Non ott Income os) Pom Operations tage of Total Net Revenue ‘Witacound AAP acme La) rom Operations
Analogic — 36th Annual JP Morgan Healthcare Conference (January 2018) on 6ix